The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10595 malaria professionals are enjoying the free benefits of MalariaWorld today

intravenous artesunate

Efficacy and Safety of Intravenous Artesunate in Children With Severe Imported Malaria

August 4, 2020 - 15:07 -- Open Access
Author(s): 
Venturini E, Zammarchi L, Bianchi L, Montagnani C, Tersigni C, Bortone B, Chiappini E, Galli L
Reference: 
Pediatr Infect Dis J. 2020 Aug; 39(8):e220

We read with interest the article by Bélard et al1 on intravenous artesunate (ivA) use for imported severe malaria in children. IvA was a highly efficacious treatment in this cohort of children, treated outside malaria-endemic region.

Delayed haemolysis after treatment with intravenous artesunate in patients with severe malaria in India

January 27, 2020 - 13:29 -- Open Access
Author(s): 
Deepali Savargaonkar, Manoj Kumar Das, Amar Verma, Jeevan K. Mitra, C. P. Yadav, Bina Srivastava, Anupkumar R. Anvikar and Neena Valecha
Reference: 
Malaria Journal 2020 19:39, 22 January 2020

Parenteral artesunate is the treatment of choice for severe malaria. It is safe, efficacious and well tolerated anti-malarial. However, delayed haemolysis has been reported in travellers, non-immune individuals and in African children.

Intravenous artesunate plus oral dihydroartemisinin–piperaquine or intravenous quinine plus oral quinine for optimum treatment of severe malaria: lesson learnt from a field hospital in Timika, Papua, Indonesia

January 6, 2020 - 16:13 -- Open Access
Author(s): 
Silvester Alexandro Sikora, Jeanne Rini Poespoprodjo, Enny Kenangalem, Daniel A. Lampah, Paulus Sugiarto, Ida Safitri Laksono, Riris Andono Ahmad and E. Elsa Herdiana Murhandarwati
Reference: 
Malaria Journal 2019 18:448, 30 December 2019

Intravenous artesunate and its follow on full course dihydroartemisinin–piperaquine are the standard treatment for severe malaria in Indonesia. The current policy suggests that intravenous and oral quinine could be used when standard therapy is not available. Its pragmatic use of both treatment combinations in a field hospital is evaluated.

NOT Open Access | Anemia and transfusion requirements among Ugandan children with severe malaria treated with intravenous artesunate

December 23, 2019 - 14:23 -- NOT Open Access
Author(s): 
Hawkes MT, Opoka RO, Conroy AL, Elphinstone RE, Hume HA, Namasopo S, Kain KC
Reference: 
Pediatr Hematol Oncol. 2019 Dec 12:1-13

Parenteral artesunate for the treatment of severe malaria in non-immune travelers is associated with late-onset hemolysis. In children in sub-Saharan Africa, the hematologic effects of malaria and artesunate are less well documented. Here we report a prospective case series of 91 children with severe malaria treated with parenteral artesunate, managed at a resource-poor hospital in Africa, with longitudinal data on hemoglobin (Hb), lactate dehydrogenase (LDH), haptoglobin, and erythrocyte morphology.

Efficacy of intravenous methylene blue, intravenous artesunate, and their combination in preclinical models of malaria

November 10, 2014 - 17:43 -- Open Access
Author(s): 
Colin Ohrt, Qigui Li, Nicanor Obaldia, Rawiwan Im-erbsin, Lisa Xie, Jonathan Berman
Reference: 
Malaria Journal 2014, 13:415 (21 October 2014)

To initiate investigation of IV MB for severe malaria, the efficacy of IV MB was compared to IV AS and to their combination in rat and non-human primate malaria models.

Subscribe to RSS - intravenous artesunate